Sernova Corp T.SVA

Echelon Confirms $3.75 Target

[steadfast]

Echelon issued a Research Note yesterday, mainting $3.75 Target advising Via-Cyte
UNLIKE , SVA, has largely demonstrated poor Clincial results to-date.
$1.12 is a bargain.  Expect  Evotec will honor  their deal  @ $2.50 August 31st, 2022.

[Metalsguy1]

Steadfast. Over decades I have never ever seen a penny stock move with any conviction based on a price target. We had a price target of 1 for years. It's Luke saying it will rain during a drought. Eventually it does but it may take years but the prediction is irrelevant. Downward pressure us unabated.. 1. Finding Waldo is more fun and easier to do than patientb7. 2. Scaling the pouch is

[BioTeck]

All the positive news that is being spread is being done through unofficial channels. I don't think it's totally belly up yet but had the Evotec deal been sealed a few months earlier, we would have been able to get out at a decent price. Things could still get a lot more ugly in the market before they turn around. Timing couldn't have been worse. Bad market, warrants, etc etc. A

[Mercuryfilling1]

 "We are bagholders in a big con game." Metals: That implies you've been outmanouvered by the same characters (Selphie, Phil etc) that you've been calling idiots for the last several years. To believe you've been conned must hurt - but to believe you've been conned by idiots must be extremely painful. Meh. Not unduly bothered by any of it. Once through the summer

[Metalsguy1]

Merc a derp. Who gave you permission to come up for air from kissing my a$$.